PolyPeptide Group AG · SIX:PPGN
PolyPeptide — H1 2021 Earnings Presentation
30 slides from PolyPeptide's earnings presentation, Aug 17, 2021
Slide 1: Business update & H1 2021 results
POLYPEPTIDE GROUP Business update & H1 2021 results 17 August 2021
Slide 2: Agenda
Agenda 1 Introduction Raymond De Vré, CEO 2 H1 Financial Results Jan Fuhr Miller, CFO 3 Priorities & Outlook Raymond De Vré, CEO 4 Q&A All 2
Slide 3: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by PolyPeptide Group AG (“PolyPeptide" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports availab
Slide 4: Agenda
Agenda 1 Introduction Raymond De Vré, CEO 2 H1 Financial Results Jan Fuhr Miller, CFO 3 Priorities & Outlook Raymond De Vré, CEO 4 Q&A All 4
Slide 5: H1 2021 with strong growth and profitability
H1 2021 with strong growth and profitability Progress with late-stage projects – accelerated capacity expansion • Revenue growth of 53.9% to € 135.1 m yoy • Progress of several late-stage custom projects, including contribution from Novavax • Further growth of project pipeline, driven by elevated cu
Slide 6: Peptide-based drugs with structural growth momentum
Peptide-based drugs with structural growth momentum Broad therapeutic areas with significant product pipeline Estimated peptide therapeutics end market ($ Bn)(1) Therapeutic areas for peptide-based drugs(1) Other Metabolic 30% 24% ~76 Drugs Approved(2) 7% CAGR ~$ 32 Bn Neurological 44 42 5% Oncology
Slide 7: Addressable peptide API market of ~$1.2 Bn with ~10% CAGR
$1.2Bn Addressable peptide API market of ~$ 1.2 Bn with ~10% CAGR Continued trend towards outsourcing and specialization Market structure(1) Industrial logic towards outsourcing Competitive dynamics In-House 35% Total Increasing risk mitigation by pharma companies Highly specialized $ 1.8 Bn Long-te
Slide 8: Agenda
Agenda 1 Introduction Raymond De Vré, CEO 2 H1 Financial Results Jan Fuhr Miller, CFO 3 Priorities & Outlook Raymond De Vré, CEO 4 Q&A All 8
Slide 9: Revenue and EBITDA development
Revenue and EBITDA development Strong momentum in H1 2021 Revenue Reported EBITDA Commentary €m € m and % margin Revenue growth of 53.9% to € 135.1 m YoY growth: 11.2% (3.2%) 53.9% YoY growth: 10.4% (18.4%) 115.4% • H1 2021 with customer activity at elevated levels • Growth across all segments, but
Slide 10: Revenue by segment
Revenue by segment Growth across segments with significant contribution from custom projects Group total revenue Custom projects revenue Contract manufacturing revenue Generics and cosmetics revenue €m €m €m Late-stage projects expected to progress into manufacturing 150 H1 2020: H1 2021: +127.5% +6
Slide 11: Adjusted EBITDA
Adjusted EBITDA 32.0% adj. EBITDA margin EBITDA Commentary €m Growth: 115.4% Operating leverage • EBITDA increase of +115.4% driven by higher revenue with favorable product mix • On a reported basis, disproportionately lower increase of cost of sales (+ 35.0%) and Margin: OPEX (+46.6%) 32.0% Adjuste
Slide 12: Time series H1 results
Time series H1 results Positive momentum seen in H1 expected to continue in H2 Summary P&L Commentary €m • 2020 with subdued H1, in comparison strong H1 2018 H1 2019 H1 2020 H1 2021 H1 2021 performance Revenue 81.6 90.7 87.8 135.1 • H1 2021 tax rate of 16.6% • Result of the period of € 24.6 m with m
Slide 13: Cash flow and cash position
Cash flow and cash position Strengthened capital position from IPO Cash balance and cash flow Commentary €m Net cash flows from operating activities (incl. NWC) of € 41.0 m, largely offset by net cash flows from investing activities of € 35.2 m • Resulting free cash flow of € 5.8 m Free cash flow: I
Slide 14: Deep dive: Capital expenditures
Deep dive: Capital expenditures Step-up in investment activities to support growth Intangible and tangible capital expenditures(1) Commentary €m Investments as H1 / H2 2020 capex impacted by coronavirus 10.8% 28.6% 18.5% % of revenue pandemic 38,7 Capital expenditures of € 25.0 m in H1 2021, at 18.5
Slide 15: Return on net operating assets
Return on net operating assets H1 2021 with favourable impacts on capital productivity RONOA and LTM operating result %/€m Avg. NOA 233.9 243.3 253.9 Operating result growth 55.8% 46.5% 25,6% Commentary 65,0 Operating performance LTM 18,2% • LTM operating result of € 65.0 m in H1 2021, reflecting st
Slide 16: Agenda
Agenda 1 Introduction Raymond De Vré, CEO 2 H1 Financial Results Jan Fuhr Miller, CFO 3 Priorities & Outlook Raymond De Vré, CEO 4 Q&A All 16
Slide 17: Current priorities to capitalize on structural opportunities
Current priorities to capitalize on structural opportunities Build capacities and capabilities to meet growing demand Let’s stay focused on the needs of our peptide customers One PolyPeptide Culture Let’s drive innovation and Let’s go for growth, also technology to stay ahead exploring new avenues P
Slide 18: Start here – stay here
Start here – stay here Be the preferred partner across the entire peptide value chain API development & manufacturing: From early phases to commercialization Drug discovery & lead Clinical development Drug product launch Pre-clinical research Commercialisation optimization Phase I Phase II Phase III
Slide 19: Growing and investing in our core business
Growing and investing in our core business Committed to increasing capacity to meet customer needs Strong pipeline for peptide therapeutics with … PolyPeptide aiming to be the …resulting in commitment to increase increasing commercial volume expectations… preferred partner… capacity and accelerate i
Slide 20: Improving cost, time, quality
Improving cost, time, quality Innovation is critical for staying ahead of the curve Culture of innovation ▪ Pre-activation, washing practices ▪ Alternative isolation technologies • Innovation culture being embedded in the organization ▪ Flow chemistry, electrochemistry • Global “Innovation and Techn
Slide 21: Addressing the emerging oligonucleotides adjacent market
Addressing the emerging oligonucleotides adjacent market On track to benefit from synergistic market opportunities Synergistic opportunities Commercial readiness around YE 2021 Significant interest expressed by leading customers; established customer relationships within overlapping customer bases I
Slide 22: Outlook
Outlook Raising guidance for full year 2021 Mid-term guidance 2021 guidance Promising structural industry trends Strong H1 2021 performance Market position with 20-25% market share Favorable environment, incl COVID Established and long-standing customer base Enhanced capacity needs Revenue Adj. EBIT
Slide 23: Agenda
Agenda 1 Introduction Raymond De Vré, CEO 2 H1 Financial Results Jan Fuhr Miller, CFO 3 Priorities & Outlook Raymond De Vré, CEO 4 Q&A All 23
Slide 24: Contact and events
Contact and events Contact Selected events in 2021 Michael Stäheli 13 – 14 September 2021 | Morgan Stanley 19th Annual Global Healthcare Conference Head of Investor Relations & Corporate Communications 3 – 5 November 2021 | ZKB Swiss Equities Conference Phone: +41 (0) 41 723 20 34 michael.staeheli@p
Slide 25: Appendix
GLOBAL SUPPORT FORA QUALITY SOLUTION Ue ioe wm
Slide 26: Consolidated statement of income
Consolidated statement of income 26
Slide 27: Consolidated statement of financial position
Consolidated statement of financial position 27
Slide 28: Consolidated statement of cash flow
Consolidated statement of cash flow 28
Slide 29: Time series HY results
Time series HY results Summary P&L €m H1 2018 H2 2018 H1 2019 H2 2019 H1 2020 H2 2020 H1 2021 Revenue 81.6 97.9 90.7 111.9 87.8 135.2 135.1 EBITDA 20.6 21.6 22.7 26.7 18.5 43.4 39.9 margin % 25.2% 22.1% 25.0% 23.8% 21.1% 32.1% 29.5% D&A (6.8) (7.7) (7.5) (8.3) (8.4) (9.2) (9.1) Operating result 13.8
Slide 30: PolyPeptide Group
3) PolyPeptide . GROUP www.polypeptide.com THE ULTIMATE PEPTIDE PARTNER